Carbox Tablets contain Oxcarbazepine 150 mg, 300 mg, or 600 mg. Oxcarbazepine is a dibenzazepine antiepileptic agent that is rapidly converted to its active metabolite, 10-monohydroxy derivative (MHD), which is responsible for its anticonvulsant activity.

Carbox Tablets provide effective seizure control as both monotherapy and adjunctive therapy in patients with epilepsy. The active metabolite stabilizes hyperexcited neuronal membranes, suppresses repetitive neuronal firing, and limits the propagation of abnormal electrical impulses. The formulation is suitable for the management of partial-onset seizures as well as generalized tonic-clonic seizures in appropriate adult and pediatric patients, offering flexible dosing based on age and clinical response.

Carbox Tablets are indicated as monotherapy and adjunctive therapy for the treatment of partial seizures in adults with epilepsy, for the treatment of generalized tonic-clonic seizures in adults and children, and as monotherapy for the treatment of partial seizures in children aged 4 to 16 years.

The antiepileptic activity of Oxcarbazepine is primarily mediated through its pharmacologically active metabolite, the 10-monohydroxy derivative (MHD). MHD blocks voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neuronal membranes, inhibition of repetitive neuronal firing, and reduction in the propagation of synaptic impulses. These actions help prevent the initiation and spread of epileptic seizures while maintaining normal neuronal function.

In adults, treatment is generally initiated at 600 mg daily in two divided doses. The dosage may be increased by 600 mg/day at weekly intervals, with a recommended maintenance dose of 1200 mg/day. During conversion to monotherapy, concomitant antiepileptic drugs should be gradually withdrawn over 3 to 6 weeks, while Carbox dosage is increased to a maximum of 2400 mg/day over 2 to 4 weeks. For pediatric patients, the recommended starting dose is 8–10 mg/kg/day in two divided doses, with gradual dose adjustments based on age, body weight, and clinical response. Dosage reduction and slower titration are recommended in patients with impaired renal function.

Carbox Tablets are contraindicated in patients with known hypersensitivity to Oxcarbazepine or any component of the formulation.